Agence Nationale De Valorisation De La Recherche (anvar)

Harvard College

Agence Nationale De Valorisation De La Recherche

Agence Nationale De Valorisation

The Agence Nationale De Valorisation De Le Recherche

Edgar Lederer

Louis A Chedid

Jean Choay

Pierre Lefrancier

Francoise Marguerite Audibert

Jean-Francois Petit

Arlette Adam

Monique Parant

Rita Ciorbaru

Frank M Berger

Pierre G Sinay

Claude Merser

Fabrielle Ellouz

Dominique Juy

Edgar Sache

Constantin Bona

Michael Sela

John R Pappenheimer

James M Krueger

Manfred L Karnovsky

Rita, Born Ciorbaru

Rita Ciorbaru Nee Sfartz

Arlette, Born Adam

Marcel Derrien

Chantal, Born Damais

Francine Parant

Pierre Le Francier

Arlette Adam, Nee Chosson

Biological compositions which induce sleep of the slow-wave type which comprise biological carriers and sleep-inducing muramyl peptides such as acetylmuramyl-L-alanyl-D-isoglutamine and derivatives thereof and methods of using such compositions.

Somnogenic compositions and method of use

The compounds have the structure 2-(2-amino or alkyl-amido-2-desoxy-3-O-D-glucopyranosyl)-alkanyl-dipeptide, possibly substituted on the saccharide residue the amino acid residue at the end of the peptide chain being a D-glutamyl residue whose .alpha.-carboxy function is esterified and .gamma.-carboxyl function amidated. The compounds are valuable as immunological medicaments.

Novel compounds of the muramyl peptide

The novel products are water-soluble oligomers, free of N-acetyl-glucosamine units, and of which the monomer elements include a group derived from muramic acid on which is fixed a chain of the peptide type including at least two aminoacyl residues, the first being selected from among: L-alanyl, L-arginyl, L-asparagyl, L-histidyl, L-hydroxyprolyl, L-isoleucyl, L-leucyl, L-methionyl, L-phenylalanyl, L-prolyl, L-seryl, L-threonyl, L-tryptophanyl, L-valyl, and the second aminoacyl is D-glutamyl or D-isoglutaminyl. They are useful for their immunoregulator properties and for the preparation of pharmaceutical compositions.

Oligomers of compounds of the muramyl-peptide type and medicaments

The invention relates to novel compounds of the muramyl-peptide type and to their uses. The muramyl-peptides according to the invention comprise at least two aminoacyl residues in the peptide chain, the second of these aminoacyl residues being D-glutamyl, and they are characterized in that the nitrogen of the first amino-acyl, and forming part of the pepetide linkage connecting the muramyl group to the peptide residue, is substituted by an alkyl group. These compounds are useful notably for the preparation of pharmaceutical compositions, in particular by reason of their regulatory properties on the immune responses of the organism.

Muramyl peptide substituted on a peptide nitrogen and medicaments

A polymer of peptidic type formed by a chain formed from aminoacyl residues preferably derived of at least one of the amino-acid residues selected from the class consisting of .alpha.,.gamma.-diaminobutyric acid, ornithine, lysine, homo-lysine, of which the lateral amino functions portionally carry peptide branches of which the aminoacyl residues are preferably derived of those selected from the class consisting of alanine, glycine, .alpha.-aminobutyric acid, valine, leucine and proline, the above-said peptide polymer having an average molecular weight comprised between about 50,000 and 250,000, and to which are bound covalently, muramyl-peptide units of which the two first aminoacid residues bound to the muramyl group are stereoisomers of the D series, the second aminoacid residue having the structure of the glutamic acid. This product is useful as anti-infectious agent.

Muramyl-peptides fixed to peptide-polymers and pharmaceutical

The invention relates to new compounds useful notably as regulator of immune responses and which are derivatives of muramyl peptides substituted at the end of the peptide chain by a group containing at least four carbon atoms.

Muramyl peptide derivatives and pharmaceutical compositions

Water soluble agents effective as immunological adjuvants for stimulating in the host the immune response to various antigens, comprising an acyl-muramic acid group, wherein acyl means acetyl or glycolyl, and a short peptide chain linked to said acyl-muramic acid group, the first and second amino acids of said peptide chain being preferentially alanine and glutamic acid respectively.

Water soluble agents effective as immunological adjuvants for

The invention relates to new compounds associating peptidyl or aminoacyl residues to lipophilic groups and pharmaceutical compositions containing said new compounds. The compounds according to the invention have the general formula: ##STR1## A preferred compound is:

Compounds associating peptidyl of aminoacyl residues to lipophilic

The invention relates to a new method for increasing the resistance of the organism to pathogenic germs and to compositions to carry out said method. In this method, one administers an effective dose of N-acetyl-muramyl-L-alanyl-D-isoglutamine or analogs responding to the formula ##STR1## wherein R.sub.1 is OH or NH.sub.2, R.sub.2 is OH, NH.sub.2 or a peptidic residue containing from 1 to 6 aminoacids, with the proviso that R.sub.1 and R.sub.2 are not simultaneously NH.sub.2.

N-Acyl-muramyl peptide derivatives having anti-infectious infections

The invention relates more particularly to the diamide of the 2-(2-acetamido-2-deoxy-3-O-D-glucopyranosyl)-D-propionyl-L-alanyl-D-glutam ic acid, to the pharmaceutical compositions containing said compound in association with a pharmaceutical vehicle. Of particular interest are the oil-free compositions containing said compound, particularly the oil-free aqueous sterile isotonic injectable solutions. These compositions are useful as adjuvants for enhancing the immune response to vaccinant antigens, particularly weak immunogens.

The invention relates to a process for obtaining agents having mitogenic and/or adjuvant properties, from Nocardia cells. According to this process Nocardia whole cells are subjected to a rupturing treatment of their walls within an aqueous medium, particularly distilled water. After the separation of the non-ruptured cells and of the wall fragments of the ruptured cells, mitogenic agents are extracted from the remaining aqueous phase. The fractions obtained are useful as laboratory reagents and for the production of medicamentous compositions in which they are associated with a pharmaceutical vehicle.

Process for obtaining agents having mitogenic and/or adjuvant properties

The adjuvant is 2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-glucopyranosyl)-D-propionyl-L- alanyl-D-isoglutamine, which compound in its .beta. glucoside form, corresponds with the formula ##STR1## It is notably useful for favoring immunitory responses relative to antigens of low immunogenicity.

Immunological adjuvant constituted by the p-amino-phenyl derivative of

The invention pertains to drug oil-free compositions, notably aqueous injectable compositions acting as non-specific adjuvants to stimulate in a host the immune responses to different antigens. The active principle of these oil-free compositions is N-acetyl-muramyl-L-alanyl-D-glutamic acid.

Growing community of inventors

Sceaux, France

Edgar Lederer